591 related articles for article (PubMed ID: 16322298)
1. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
2. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
3. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations.
Faridoni-Laurens L; Tourpin S; Alsafadi S; Barrois M; Temam S; Janot F; Koscielny S; Bosq J; Bénard J; Ahomadegbe JC
Cell Cycle; 2008 Jun; 7(11):1587-96. PubMed ID: 18469517
[TBL] [Abstract][Full Text] [Related]
4. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
Bar JK; Harłozińska A; Popiela A; Noga L
Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer.
Hofstetter G; Berger A; Fiegl H; Slade N; Zorić A; Holzer B; Schuster E; Mobus VJ; Reimer D; Daxenbichler G; Marth C; Zeimet AG; Concin N; Zeillinger R
Oncogene; 2010 Apr; 29(13):1997-2004. PubMed ID: 20101229
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature.
Hofstetter G; Berger A; Chamson M; Müller-Holzner E; Reimer D; Ulmer H; Uramoto H; Marth C; Zeimet AG; Zeillinger R; Concin N
Int J Gynecol Pathol; 2011 Nov; 30(6):527-31. PubMed ID: 21979586
[TBL] [Abstract][Full Text] [Related]
7. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
Ibrahim N; He L; Leong CO; Xing D; Karlan BY; Swisher EM; Rueda BR; Orsulic S; Ellisen LW
Cancer Res; 2010 Sep; 70(18):7155-65. PubMed ID: 20807817
[TBL] [Abstract][Full Text] [Related]
8. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.
Zaika AI; Slade N; Erster SH; Sansome C; Joseph TW; Pearl M; Chalas E; Moll UM
J Exp Med; 2002 Sep; 196(6):765-80. PubMed ID: 12235210
[TBL] [Abstract][Full Text] [Related]
9. Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer.
Marabese M; Marchini S; Marrazzo E; Mariani P; Cattaneo D; Fossati R; Compagnoni A; Signorelli M; Moll UM; Codegoni AM; Broggini M
Eur J Cancer; 2008 Jan; 44(1):131-41. PubMed ID: 18039564
[TBL] [Abstract][Full Text] [Related]
10. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers.
Becker K; Pancoska P; Concin N; Vanden Heuvel K; Slade N; Fischer M; Chalas E; Moll UM
Int J Oncol; 2006 Oct; 29(4):889-902. PubMed ID: 16964385
[TBL] [Abstract][Full Text] [Related]
11. p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade.
Nozaki M; Tada M; Kashiwazaki H; Hamou MF; Diserens AC; Shinohe Y; Sawamura Y; Iwasaki Y; de Tribolet N; Hegi ME
Brain Pathol; 2001 Jul; 11(3):296-305. PubMed ID: 11414472
[TBL] [Abstract][Full Text] [Related]
12. P73 gene expression in ovarian cancer tissues and cell lines.
Chen CL; Ip SM; Cheng D; Wong LC; Ngan HY
Clin Cancer Res; 2000 Oct; 6(10):3910-5. PubMed ID: 11051237
[TBL] [Abstract][Full Text] [Related]
13. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
[TBL] [Abstract][Full Text] [Related]
14. TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells.
Lai J; Yang F; Zhang W; Wang Y; Xu J; Song W; Huang G; Gu J; Guan X
Mol Cells; 2014 Aug; 37(8):605-12. PubMed ID: 25134538
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival.
Pieretti M; Hopenhayn-Rich C; Khattar NH; Cao Y; Huang B; Tucker TC
Cancer Invest; 2002; 20(1):11-23. PubMed ID: 11852993
[TBL] [Abstract][Full Text] [Related]
16. [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):107-10. PubMed ID: 16750013
[TBL] [Abstract][Full Text] [Related]
17. Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.
Zavarikina TM; Khokhlova SV; Tyulyandina AS; Khabas GN; Asaturova AV; Nosova YV; Brenner PK; Kapralova MA; Khodirev DS; Stenina MB
Bull Exp Biol Med; 2021 Oct; 171(6):755-759. PubMed ID: 34709513
[TBL] [Abstract][Full Text] [Related]
18. Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer.
Nadkarni NJ; Geest KD; Neff T; Young BD; Bender DP; Ahmed A; Smith BJ; Button A; Goodheart MJ
Cancer Lett; 2013 Apr; 331(1):99-104. PubMed ID: 23268330
[TBL] [Abstract][Full Text] [Related]
19. One, two, three--p53, p63, p73 and chemosensitivity.
Müller M; Schleithoff ES; Stremmel W; Melino G; Krammer PH; Schilling T
Drug Resist Updat; 2006 Dec; 9(6):288-306. PubMed ID: 17287142
[TBL] [Abstract][Full Text] [Related]
20. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1.
Domínguez G; García JM; Peña C; Silva J; García V; Martínez L; Maximiano C; Gómez ME; Rivera JA; García-Andrade C; Bonilla F
J Clin Oncol; 2006 Feb; 24(5):805-15. PubMed ID: 16380414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
